Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study
Following encouraging updates from the ongoing Phase 1b PIONEER study evaluating pociredir in sickle cell disease, analyst sentiment around Fulcrum Therapeutics, Inc.



